MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer.
MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer.
复制标题
DOI：
10.1186/s12935-017-0431-9
复制
发表时间：
2017
影响因子：
5.8
通讯作者：
Zuo M
中科院分区：
文献类型：
--
作者：
Chen AH;Qin YE;Tang WF;Tao J;Song HM;Zuo M
最近的证据表明，microRNA的异常表达在宫颈癌的发生发展中起着至关重要的作用。总的较短生存期与靶向B细胞淋巴瘤-2(Bcl2)和c-Met的microRNA-34a(miR-34a)和microRNA-206(miR-206)的异常表达密切相关。肝细胞生长因子(HGF)/c-Met通路与宫颈癌的发生、发展及预后有关，而c-Met在宫颈鳞癌中明显过表达。BCL2也被认为是开发新的抗癌治疗的一个有前途的靶点。本研究通过实时定量聚合酶链式反应(qRT-PCR)检测miR-34a和miR-206在宫颈癌组织中的表达，并用免疫组织化学方法检测bcl2和c-Met在宫颈癌组织中的表达。定量逆转录聚合酶链式反应显示miR-34a和miR-206在宫颈癌组织中表达下调。Bcl2和c-Met作为miR-34a和miR-206的靶基因，通过qRT-PCR和免疫组织化学方法在宫颈癌组织中表达上调。Kaplan-Meier和LOG-RANK分析显示miR-34a和miR-206表达下调与总生存期缩短密切相关。单因素分析中具有统计学意义的多因素COX比例风险模型显示，miR-34a(P=0.038)和miR-206(P=0.008)可能是影响宫颈癌患者总体生存的独立预后因素。Bcl2和c-Met的表达上调促进了宫颈癌的进展，miR-34a和miR-206的表达与宫颈癌的进展和预后密切相关。提示miR-34a和miR-206有可能成为宫颈癌预后判断和治疗的新工具。本文的在线版本(doi：10.1186/s12935-0170431-9)包含补充材料，授权用户可以使用。
Recent evidence indicated that the aberrant expression of microRNA plays a crucial role in the development of cervical cancer. The overall shorter survival was strongly related to the abnormal expression of microRNA-34a (miR-34a) and microRNA-206 (miR-206), which target B cell lymphoma-2(Bcl2) and c-Met. Hepatocyte growth factor (HGF)/c-Met pathway is related to the occurrence, development and prognosis of cervical cancer, and c-Met is significantly overexpressed in cervical squamous cell carcinoma. Bcl2 is also considered to be a promising target for developing novel anticancer treatments. In this study, we detect the expression of miR-34a and miR-206 in the cervical cancer tissue through quantificational real-time polymerase chain reaction (qRT-PCR) assay, and the expression of Bcl2 and c-Met from cervical cancer tissue were detected by immunohistochemistry. The expression of miR-34a and miR-206 were down-regulated in the cervical cancer tissue through qRT-PCR assay. As target genes of miR-34a and miR-206, Bcl2 and c-Met were up-regulated in cervical cancer tissues through qRT-PCR assay and immunohistochemistry. Kaplan–Meier and log-rank analysis revealed that down-regulated expression of miR-34a and miR-206 were strongly related to shorter overall survival. Multivariate Cox proportional hazards model for all variables that were statistically significant in the univariate analysis demonstrated that miR-34a (P = 0.038) and miR-206 (P = 0.008) might be independent prognostic factors for overall survival of patients suffering from cervical cancer. The up-regulation of Bcl2 and c-Met promotes the cervical cancer’s progress, and the expression of miR-34a and miR-206 significantly correlated with the progression and prognosis in cervical cancer. All of these suggested that miR-34a and miR-206 might be the novel prognostic and therapy tools in cervical cancer. The online version of this article (doi:10.1186/s12935-017-0431-9) contains supplementary material, which is available to authorized users.